Haven't used GeneWake GmbH yet?
Ask Trustburn

Ask Trustburn about GeneWake GmbH

Based on 8 reviews on Trustburn

Based on reviews on this page. Verify anything important with the company directly.

Judith Partridge
Reviews 1

GeneWake GmbH is a reliable company to work with. I appreciate their prompt responses and attention to detail. The team was able to fulfill all my requirements and delivered exceptional results. I would highly recommend them to anyone in need of their services.

Barb Meade
Reviews 1

I had a really positive experience with GeneWake GmbH. Their website is user-friendly and easy to navigate. The information provided was detailed and accurate. The customer service was also great, they were responsive and helpful in answering my questions. Overall, I highly recommend GeneWake GmbH!

Tony Kaus
Reviews 1

The service provided by this company was exceptional. I was impressed with the efficiency and professionalism of their team. They were able to meet all of my requirements and delivered high-quality results. Definitely one of the best experiences I've had with a company.

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="genewake-com" data-lang="en"></div>
More widgets

About GeneWake GmbH

GeneWake GmbH focuses on contract research in the vast field of biomarker analysis for oncology. We specialize in biomarker prescreening for patient stratification to ensure the best possible care for cancer patients. By employing bioinformatical algorithms based on knowledge in pathway structure and microarray data from public sources, it is possible to limit biomarker screening to analysis on a low-density scale. This is not only cost efficient, but also more easily interpreted compared to high-density
methods like whole genome microarrays. Samples can be anything from fresh frozen or paraffin embedded tissue to whole blood. A typical output of a study would be a short list of 10-20 potential biomarkers, that are highly likely to carry changes on the DNA or protein level.